SCHEMBL47601

SCHEMBL47601

CN(CCN(CCN)CCN)C(=O)c1ccccc1C(=O)C(C)(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.39
ATM Q13315 1/20 0.39
CHEK1 O14757 1/20 0.39
TP53 P04637 1/20 0.37
KMT2A Q03164 3/20 0.35
HPGD P15428 2/20 0.35
TNFSF11 O14788 1/20 0.34
MEN1 O00255 2/20 0.34
ALDH1A1 P00352 1/20 0.34
MLYCD O95822 1/20 0.34
TACR1 P25103 4/20 0.33
KIF11 P52732 1/20 0.33
CDK4 P11802 2/20 0.33
CCND1 P24385 2/20 0.33
F2 P00734 1/20 0.33
F10 P00742 1/20 0.33
CYP1A2 P05177 1/20 0.33
GAA P10253 1/20 0.33
TSHR P16473 1/20 0.33
DRD4 P21917 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24098114 0.84 CHEK1 (0.41) KDM4EATMCHEK1TP53KMT2A
SCHEMBL47600 0.84 KDM4E (0.43) KDM4EATMTP53KMT2AHPGD
SCHEMBL20355737 0.84 CHEK1 (0.37) KDM4EATMCHEK1TP53KMT2A
SCHEMBL18588479 0.77 ALDH1A1 (0.52) KDM4EHPGDALDH1A1TSHRCYP2C19
SCHEMBL1822372 0.71 TSHR (0.47) KDM4ECHEK1TP53KMT2AHPGD
SCHEMBL15445468 0.71 ELANE (0.47) KDM4ETP53KMT2AMEN1ALDH1A1
SCHEMBL12305556 0.69 ALDH1A1 (0.48) KDM4EATMTP53KMT2AHPGD
SCHEMBL8552380 0.68 TP53 (0.52) KDM4EATMTP53KMT2AHPGD
SCHEMBL18566583 0.68 TP53 (0.49) KDM4ETP53HPGDALDH1A1GAA
SCHEMBL47640 0.68 OPRM1 (0.39) KDM4EATMKMT2AMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170112939-A1 PREVENTION AND TREATMENT OF OCULAR CONDITIONS Ascendis Pharma Ophthamology Division A/S (DK) 2017-04-27 US disclosed
US-20170100490-A1 Prodrug Comprising a Drug Linker Conjugate ASCENDIS PHARMA A/S (DK) 2017-04-13 US disclosed
US-9511122-B2 Dry growth hormone composition transiently linked to a polymer carrier ASCENDIS PHARMA GROWTH DISORDERS DIVISION A/S (DK) 2016-12-06 US disclosed
US-20160206702-A1 PEGylated Recombinant Human Growth Hormone Compounds ASCENDIS PHARMA GROWTH DISORDERS DIVISION A/S (DK) 2016-07-21 US disclosed
US-9272048-B2 PEGylated recombinant human growth hormone compounds ASCENDIS PHARMA GROWTH DISORDERS DIVISION A/S (DK) 2016-03-01 US disclosed
US-20150290337-A1 DIAGNOSIS, PREVENTION AND TREATMENT OF DISEASES OF THE JOINT ASCENDIS PHARMA INC. 2015-10-15 US disclosed
US-20150057221-A1 PRODRUG COMPRISING A DRUG LINKER CONJUGATE ASCENDIS PHARMA AS (DK) 2015-02-26 US disclosed
US-20150010634-A1 PREVENTION AND TREATMENT OF OCULAR CONDITIONS Ascendis Pharma Ophthamology Division A/S (DK) 2015-01-08 US disclosed
US-8906847-B2 Prodrug comprising a drug linker conjugate ASCENDIS PHARMA A/S (DK) 2014-12-09 US disclosed
US-20140323402-A1 Protein Carrier-Linked Prodrugs Ascendis Phama A/S (DK) 2014-10-30 US disclosed
US-20140296257-A1 High-Loading Water-Soluable Carrier-Linked Prodrugs ASCENDIS PHARMA A/S (DK) 2014-10-02 US disclosed
US-20140243254-A1 Polymeric Hyperbranched Carrier-Linked Prodrugs ASCENDIS PHARMA A/S (DK) 2014-08-28 US disclosed
US-20120322721-A1 DRY GROWTH HORMONE COMPOSITION TRANSIENTLY LINKED TO A POLYMER CARRIER ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S (DK) 2012-12-20 US disclosed
US-20120156259-A1 Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels ASCENDIS PHARMA A/S (DK) 2012-06-21 US disclosed
US-20120058084-A1 Interferon Alpha Carrier Prodrugs ASCENDIS PHARMA AS (DK) 2012-03-08 US disclosed
US-20110112021-A1 PEGYLATED RECOMBINANT HUMAN GROWTH HORMONE COMPOUNDS ASCENDIS PHARMA AS (DK) 2011-05-12 US disclosed
US-20110053848-A1 PRODRUG COMPRISING A DRUG LINKER CONJUGATE ASCENDIS PHARMA AS (DK) 2011-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140296257-A1 High-Loading Water-Soluable Carrier-Linked Prodrugs ABCB11, SLCO1B1, SLC7A1 KDM4E 3887/4885ATM 4841/4885CHEK1 4349/4885
US-20170112939-A1 PREVENTION AND TREATMENT OF OCULAR CONDITIONS PDE6C, ALDH1A2, UACA KDM4E 4186/4885ATM 3069/4885CHEK1 1726/4885
US-20120322721-A1 DRY GROWTH HORMONE COMPOSITION TRANSIENTLY LINKED TO A POLYMER CARRIER GHRHR, GHSR, GCG KDM4E 2150/4885ATM 3497/4885CHEK1 2208/4885
US-20120156259-A1 Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels PLG, PHYKPL, PLOD3 KDM4E 1756/4885ATM 2090/4885CHEK1 1266/4885
US-20150290337-A1 DIAGNOSIS, PREVENTION AND TREATMENT OF DISEASES OF THE JOINT ADAMTS13, ADAMTS5, TNF KDM4E 4331/4885ATM 4246/4885CHEK1 4730/4885
US-20150057221-A1 PRODRUG COMPRISING A DRUG LINKER CONJUGATE H1-0, H1-3, H1-2 KDM4E 1446/4885ATM 4184/4885CHEK1 4094/4885
US-20170100490-A1 Prodrug Comprising a Drug Linker Conjugate H1-0, H1-3, H1-2 KDM4E 1446/4885ATM 4184/4885CHEK1 4094/4885
US-20110112021-A1 PEGYLATED RECOMBINANT HUMAN GROWTH HORMONE COMPOUNDS GHRHR, GHITM, GHSR KDM4E 3989/4885ATM 3471/4885CHEK1 3085/4885
US-20160206702-A1 PEGylated Recombinant Human Growth Hormone Compounds GHRHR, GHITM, GHSR KDM4E 3989/4885ATM 3471/4885CHEK1 3085/4885
US-20140243254-A1 Polymeric Hyperbranched Carrier-Linked Prodrugs P4HA1, CYP8B1, PAH KDM4E 3467/4885ATM 4290/4885CHEK1 3345/4885
US-20110053848-A1 PRODRUG COMPRISING A DRUG LINKER CONJUGATE H1-0, H1-3, H1-2 KDM4E 1429/4885ATM 4195/4885CHEK1 4127/4885
US-20140323402-A1 Protein Carrier-Linked Prodrugs SLC6A7, PRAP1, PELP1 KDM4E 4594/4885ATM 2145/4885CHEK1 2084/4885
US-20150010634-A1 PREVENTION AND TREATMENT OF OCULAR CONDITIONS PDE6C, ALDH1A2, UACA KDM4E 4186/4885ATM 3069/4885CHEK1 1726/4885
US-20120058084-A1 Interferon Alpha Carrier Prodrugs IFNG, IFNAR1, IRF3 KDM4E 4661/4885ATM 4595/4885CHEK1 3241/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.